{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:36:38Z","timestamp":1774935398305,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Danon disease is an X-linked dominant vacuolar disease caused by a mutation in lysosome-associated membrane protein-2 (LAMP-2). LAMP-2 has 3 known subtypes, with LAMP-2B being the most important in Danon disease. It plays a role in macroautophagy and is one of the reasons why those with Danon disease have issues degrading cytoplasmic components. Autophagic vacuoles with unique sacrolemmal features are a characteristic finding in Danon disease. This condition is rare but causes fatal cardiomyopathy in those it affects. It is known to cause a triad of intellectual disability, cardiomyopathy, and skeletal myopathy in males, but is mostly restricted to cardiomyopathy in females. The cardiomyopathy is most often hypertrophic cardiomyopathy, but can also be dilated cardiomyopathy, especially in females. Both ventricular and atrial arrhythmias are common in those with Danon disease. They commonly have slurring of the upstroke of the QRS complex, or ventricular depolarization, on electrocardiogram and extensive late gadolinium uptake with mid-interventricular septal sparing on cardiac magnetic resonance imaging. Treatment currently consists of heart transplant, and gene therapy studies are in phase II clinical trials using RP-A501, a recombinant adeno-associated virus-9 containing the transgene LAMP-2, to deliver LAMP-2 to cardiomyocytes.<\/jats:p>","DOI":"10.1097\/crd.0000000000001253","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:00:55Z","timestamp":1774929655000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Danon Disease: Clinical Manifestations, Pathophysiology, and Treatment"],"prefix":"10.1097","author":[{"given":"Margot","family":"Richards","sequence":"first","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Tetelbaun","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"R1-20260331","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.31.1.51","article-title":"Lysosomal glycogen storage disease with normal acid maltase.","volume":"31","author":"Danon","year":"1981","journal-title":"Neurology"},{"key":"R2-20260331","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"R3-20260331","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/biom14101272","article-title":"History and perspective of LAMP-2 deficiency (Danon Disease).","volume":"14","author":"Sugie","year":"2024","journal-title":"Biomolecules"},{"key":"R6-20260331","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/ijms19113507","article-title":"A nationwide survey on Danone disease in Japan.","volume":"19","author":"Sugie","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R7-20260331","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues.","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"R8-20260331","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tcm.2021.10.012","article-title":"Clinical features of Danon disease and insights gained from LAMP-2 deficiency models.","volume":"33","author":"Zhai","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"R9-20260331","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00401-015-1385-4","article-title":"Danon disease: a phenotypic expression of LAMP-2 deficiency.","volume":"129","author":"Endo","year":"2015","journal-title":"Acta Neuropathol"},{"key":"R10-20260331","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1091\/mbc.e02-02-0114","article-title":"Role of LAMP-2 in lysosome biogenesis and autophagy.","volume":"13","author":"Eskelinen","year":"2002","journal-title":"Mol Biol Cell"},{"key":"R11-20260331","doi-asserted-by":"crossref","first-page":"102015","DOI":"10.1016\/j.disamonth.2025.102015","article-title":"Danon disease: from genetic origins and molecular defects to therapeutic advances.","volume":"71","author":"Chaudhary","year":"2025","journal-title":"Dis Mon"},{"key":"R12-20260331","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","article-title":"Danon disease: gender differences in presentation and outcomes.","volume":"286","author":"Brambatti","year":"2019","journal-title":"Int J Cardiol"},{"key":"R13-20260331","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/WNL.58.12.1773","article-title":"Clinicopathological features of genetically confirmed Danone disease.","volume":"58","author":"Sugie","year":"2002","journal-title":"Neurology"},{"key":"R14-20260331","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/ajmg.a.38320","article-title":"Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation).","volume":"173","author":"Yardeni","year":"2017","journal-title":"Am J Med Genet A"},{"key":"R15-20260331","doi-asserted-by":"crossref","first-page":"e038394","DOI":"10.1161\/JAHA.124.038394","article-title":"An international longitudinal natural history study of patients with Danon disease: unique cardiac trajectories identified based on sex and heart failure outcomes.","volume":"14","author":"Hong","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R16-20260331","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2020.08.011","article-title":"Cardiac magnetic resonance imaging in Danon disease cardiomyopathy.","volume":"14","author":"Rigolli","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"R17-20260331","first-page":"1204","article-title":"Cardiac arrhythmias in patients with Danon disease.","volume":"19","author":"Konrad","year":"2017","journal-title":"Europace"},{"key":"R18-20260331","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/jce.14049","article-title":"Arrhythmias and fasciculoventricular pathways in patients with Danon disease: a single center experience.","volume":"30","author":"Jhaveri","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R19-20260331","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/genes14081539","article-title":"Danon disease: entire LAMP2 gene deletion with unusual clinical presentation-case report and review of the literature.","volume":"14","author":"Shalata","year":"2023","journal-title":"Genes"},{"key":"R22-20260331","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cardfail.2021.11.007","article-title":"Cardiac transplantation in Danon disease.","volume":"28","author":"Hong","year":"2022","journal-title":"J Card Fail"},{"key":"R23-20260331","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMe2415793","article-title":"Genetic medicine for Danon disease.","volume":"392","author":"McNally","year":"2025","journal-title":"N Engl J Med"},{"key":"R24-20260331","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9.","volume":"86","author":"DiMattia","year":"2012","journal-title":"J Virol"},{"key":"R25-20260331","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease.","volume":"392","author":"Greenberg","year":"2025","journal-title":"N Engl J Med"},{"key":"R27-20260331","doi-asserted-by":"crossref","first-page":"115735","DOI":"10.1016\/j.bcp.2023.115735","article-title":"Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.","volume":"215","author":"Yadin","year":"2023","journal-title":"Biochem Pharmacol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:01:00Z","timestamp":1774929660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001253","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}